Tokyo's benchmark Nikkei 225 index has fallen more than 4% and other shares in Asia also sank after a retreat on Wall Street ...
Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...
Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback